- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-IL12B/ CLMF/ CLMF2 functional antibody
Anti-IL12B/ CLMF/ CLMF2 functional antibody for cell culture, ELISA & in-vivo assay
Go to IL12B/IL12B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T95385-Ab-1/ GM-Tg-hg-T95385-Ab-2 | Anti-Human IL12B monoclonal antibody | Human |
| GM-Tg-rg-T95385-Ab-1/ GM-Tg-rg-T95385-Ab-2 | Anti-Rat IL12B monoclonal antibody | Rat |
| GM-Tg-mg-T95385-Ab-1/ GM-Tg-mg-T95385-Ab-2 | Anti-Mouse IL12B monoclonal antibody | Mouse |
| GM-Tg-cynog-T95385-Ab-1/ GM-Tg-cynog-T95385-Ab-2 | Anti-Cynomolgus/ Rhesus macaque IL12B monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T95385-Ab-1/ GM-Tg-felg-T95385-Ab-2 | Anti-Feline IL12B monoclonal antibody | Feline |
| GM-Tg-cang-T95385-Ab-1/ GM-Tg-cang-T95385-Ab-2 | Anti-Canine IL12B monoclonal antibody | Canine |
| GM-Tg-bovg-T95385-Ab-1/ GM-Tg-bovg-T95385-Ab-2 | Anti-Bovine IL12B monoclonal antibody | Bovine |
| GM-Tg-equg-T95385-Ab-1/ GM-Tg-equg-T95385-Ab-2 | Anti-Equine IL12B monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T95385-Ab-1/ GM-Tg-hg-T95385-Ab-2; GM-Tg-rg-T95385-Ab-1/ GM-Tg-rg-T95385-Ab-2; GM-Tg-mg-T95385-Ab-1/ GM-Tg-mg-T95385-Ab-2; GM-Tg-cynog-T95385-Ab-1/ GM-Tg-cynog-T95385-Ab-2; GM-Tg-felg-T95385-Ab-1/ GM-Tg-felg-T95385-Ab-2; GM-Tg-cang-T95385-Ab-1/ GM-Tg-cang-T95385-Ab-2; GM-Tg-bovg-T95385-Ab-1/ GM-Tg-bovg-T95385-Ab-2; GM-Tg-equg-T95385-Ab-1/ GM-Tg-equg-T95385-Ab-2 |
| Products Name | Anti-IL12B monoclonal antibody |
| Format | mab |
| Target Name | IL12B |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-IL12B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-605 | Pre-Made Ustekinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-081 | Pre-Made Briakinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-162 | Pre-Made Ebdarokimab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody |
| Target Antigen | GM-Tg-g-T95385-Ag-1 | Recombinant multi-species IL12B/ CLMF/ CLMF2 protein |
| Cytokine | GM-Tg-g-T95385-Ag-1 | Interleukin 12b (IL12B) protein |
| ORF Viral Vector | pGMLP000740 | human IL12B Lentivirus plasmid |
| ORF Viral Vector | vGMLP000740 | human IL12B Lentivirus particle |
Target information
| Target ID | GM-T95385 |
| Target Name | IL12B |
| Gene ID | 3593,16160,64546,694747,403976,768273,281857,100034222 |
| Gene Symbol and Synonyms | CLMF,CLMF2,IL-12.p40,IL-12B,Il-12p40,Il12,IL12B,Il12p40,IMD28,IMD29,NKSF,NKSF2,p40 |
| Uniprot Accession | P29460,P48095,Q28268,O02744,P46282,Q9XSQ5 |
| Uniprot Entry Name | IL12B_HUMAN,IL12B_MACMU,IL12B_FELCA,IL12B_CANLF,IL12B_BOVIN,IL12B_HORSE |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000113302 |
| Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: IL12B, gene name: IL12B, also named as CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2. This gene encodes a subunit of interleukin 12, a cytokine that acts on T and natural killer cells, and has a broad array of biological activities. Interleukin 12 is a disulfide-linked heterodimer composed of the 40 kD cytokine receptor like subunit encoded by this gene, and a 35 kD subunit encoded by IL12A. This cytokine is expressed by activated macrophages that serve as an essential inducer of Th1 cells development. This cytokine has been found to be important for sustaining a sufficient number of memory/effector Th1 cells to mediate long-term protection to an intracellular pathogen. Overexpression of this gene was observed in the central nervous system of patients with multiple sclerosis (MS), suggesting a role of this cytokine in the pathogenesis of the disease. The promoter polymorphism of this gene has been reported to be associated with the severity of atopic and non-atopic asthma in children. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
